Business Wire

Svante and Södra Launch EU-Based Carbon Capture Pilot to Advance Biogenic CO₂ Utilization

10.11.2025 22:49:00 CET | Business Wire | Press Release

Share

Svante Technologies Inc. (“Svante”), a global leader in solid sorbent-based carbon capture and removal solutions, is proud to share that Södra, Sweden’s largest forest-owner association, has announced it will test Svante’s carbon capture technology at the Värö industrial site in early 2026 and evaluate opportunities for large-scale capture in the future.

This pilot project marks Svante’s first deployment in the EU forestry sector and represents a significant step toward scaling biogenic carbon capture in pulp and paper production. The pilot will evaluate the performance of Svante’s proprietary solid sorbent filters in capturing biogenic CO₂ emissions from Södra’s pulp operations, with the goal of enabling new circular value chains and supporting Sweden’s climate targets.

A Strategic Step Toward Circular Bioeconomy

Södra’s pulp production generates biogenic CO₂, which is a renewable carbon source with potential applications across food, water purification, chemical manufacturing, and e-fuels. By capturing and refining this CO₂, the pilot aims to unlock new revenue streams and extend the value of forest raw materials without increasing harvesting.

“Carbon capture is no longer just about emissions reduction — it’s about resource efficiency and climate-positive innovation,” said Mark Claessen, President of Svante’s business unit, Svante Solutions & Digital Services. “Jointly with Södra we have the potential to capture and remove over one million tonnes of biogenic CO₂ annually. We’re excited to work on this project to demonstrate how our sustainable high-performance capture technology can help decarbonize industrial operations at commercial scale.”

Technology Deployment and Full-Value Chain Testing

The test facility will be installed at Södra’s Värö site and operated in collaboration with the Swedish research institute RISE, which will support liquefaction trials of the captured CO₂. This will enable the project team to evaluate the full value chain — from capture to compression and liquefaction — and assess the feasibility of scaling up for permanent storage or downstream use.

“By conducting trials with Svante’s technology in our own environment, we’re building expertise tailored to our operations,” said Jenny Gotthardsson, General Manager at Södra Cell Värö. “This is an important step in strengthening our competitiveness and the profitability of forest estates.”

EU Support and Climate Impact

The project is partially funded through Industriklivet, part of the EU’s Recovery and Resilience Facility (RRF) under the Next Generation EU programme. It aligns with Sweden’s national climate strategy and Södra’s long-term commitment to sustainable forestry and innovation.

This pilot reinforces Svante’s mission to commercialize Canadian-made cleantech globally and accelerate the deployment of carbon capture and solutions across industries and borders.

About Svante

Svante is a purpose-driven, leading carbon capture and removal solutions provider. The company makes nanoengineered filters and modular rotating contactor machines that capture and remove CO₂ in an environmentally responsible way from industrial emissions and the air. Svante is on the 2025 Global Cleantech 100 and TIME & Statista’s list of Top Greentech Companies of 2025. For more information, visit www.svanteinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110488946/en/

Contacts

Svante
Colleen Nitta
Director, Marketing & Communications
cnitta@svanteinc.com
+1-604-970-2813

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye